Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
McClements L, Yakkundi A, Papaspyropoulos A, Harrison H, Ablett MP, Jithesh PV, McKeen HD, Bennett R, Donley C, Kissenpfennig A, McIntosh S, McCarthy HO, O'Neill E, Clarke RB, Robson T. McClements L, et al. Clin Cancer Res. 2013 Jul 15;19(14):3881-93. doi: 10.1158/1078-0432.CCR-13-0595. Epub 2013 Jun 5. Clin Cancer Res. 2013. PMID: 23741069
FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis.
Yakkundi A, Bennett R, Hernández-Negrete I, Delalande JM, Hanna M, Lyubomska O, Arthur K, Short A, McKeen H, Nelson L, McCrudden CM, McNally R, McClements L, McCarthy HO, Burns AJ, Bicknell R, Kissenpfennig A, Robson T. Yakkundi A, et al. Among authors: mcclements l. Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):845-54. doi: 10.1161/ATVBAHA.114.304539. Epub 2015 Mar 12. Arterioscler Thromb Vasc Biol. 2015. PMID: 25767277 Free PMC article.
FKBPL: a marker of good prognosis in breast cancer.
Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T. Nelson L, et al. Among authors: mcclements l. Oncotarget. 2015 May 20;6(14):12209-23. doi: 10.18632/oncotarget.3528. Oncotarget. 2015. PMID: 25906750 Free PMC article.
RALA-mediated delivery of FKBPL nucleic acid therapeutics.
Bennett R, Yakkundi A, McKeen HD, McClements L, McKeogh TJ, McCrudden CM, Arthur K, Robson T, McCarthy HO. Bennett R, et al. Among authors: mcclements l. Nanomedicine (Lond). 2015 Oct;10(19):2989-3001. doi: 10.2217/nnm.15.115. Epub 2015 Sep 30. Nanomedicine (Lond). 2015. PMID: 26419658 Free PMC article.
FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer.
Annett S, Moore G, Short A, Marshall A, McCrudden C, Yakkundi A, Das S, McCluggage WG, Nelson L, Harley I, Moustafa N, Kennedy CJ, deFazio A, Brand A, Sharma R, Brennan D, O'Toole S, O'Leary J, Bates M, O'Riain C, O'Connor D, Furlong F, McCarthy H, Kissenpfennig A, McClements L, Robson T. Annett S, et al. Among authors: mcclements l. Br J Cancer. 2020 Feb;122(3):361-371. doi: 10.1038/s41416-019-0649-5. Epub 2019 Nov 27. Br J Cancer. 2020. PMID: 31772325 Free PMC article.
60 results